Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for pegunigalsidase alfa

  1. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915

  2. Pegunigalsidase alfa every 4 weeks for treating Fabry disease [TSID12346]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Topic prioritisation

    Find out what guidance is being considered for development